Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$9.10 ▼ -0.04
(-0.44%)
MKT CAP: $151.6M • VOL: 122.4K
52W L $7 52W H $44
ROARABLE / RQD
D- • 36/100
PIOTROSKI
4 / 9
STRO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $102.5M | $62.0M | $153.7M |
| YoY Revenue Growth % | +65.2% | -59.6% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$158.4M | -$238.5M | -$89.3M |
| Operating Margin % | -80.0% | -80.0% | -58.1% |
| Net Income (GAAP) | -$191.0M | -$227.0M | -$107.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$177.2M | -$191.5M | -$111.6M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$177.2M | -$191.5M | -$111.6M |
| FCF Margin % | -80.0% | -80.0% | -72.6% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $58.1M | $190.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$132.5M | $44.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR STRO.